• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >Use of Recombinant DNA (Deoxyribonucleic Acid) Techniques for the Production of a More Effective Anthrax Vaccine
【24h】

Use of Recombinant DNA (Deoxyribonucleic Acid) Techniques for the Production of a More Effective Anthrax Vaccine

机译：使用重组DNa（脱氧核糖核酸）技术生产更有效的炭疽疫苗

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The authors report an improved isolation procedure for the preparation of pX01 and pX02 plasmids of B. anthracis. These plasmids have been physically characterized with regard to buoyant density, GC content and size analysis using restriction enzyme digestions. Restriction maps of these DNAs have been generated. pX01 is 175 kbp and pX02 is 95 kbp. The location of the toxin genes, protective antigen (PA), lethal factor (LF) and edema factor (EF), have been positioned on pX01. The EF gene has been cloned and sequenced. Unique features of the EF gene include a putative ATP binding site. Expression vectors in E. coli have been used to produce large quantities of this protein. Expression vectors for LF and PA in both E. and coli and B. subtilis have been used for enhanced expression of these genes as well. In order to generate a safe anthrax vaccine using recombinant DNA techniques, we have begun experiments to specifically mutant each of these toxin genes to generate non-functional proteins that retain most, if not all, of their immunogenic properties. For example, the trypsin cleavage site of PA is being altered to remove the Arg-Lys-Lys-Arg sequence which is cleaved to activate PA. In addition, the putative ATP binding site of EF is being mutated to prevent enzyme activity. These experiments should generate mutant toxin proteins which will be safe vaccine components which will then be tested in animals.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号